Better Medicine, Together

Most trusted partner in therapeutic drug discovery with fully integrated services and cutting-edge platform technologies across multiple modalities

Empowering drug discovery and development through AI/ML-driven innovation and integrated solutions

We support partners and collaborators with AI-enabled discovery platforms, foundational technologies, and fully integrated wet and dry lab services. With expertise across multiple modalities, we confidently tackle challenging programs and deliver success backed by years of scientific and operational excellence.

Alloy Therapeutics drug discovery banner
AI/ML

Accelerating discovery with Alloy’s integrated AI/ML

Alloy Therapeutics embeds AI/ML directly into the core of our discovery and development platforms, uniting predictive modeling with a global wet-lab engine to drive real biological outcomes. Trained on one of the industry’s largest proprietary experimental datasets, our models shorten design cycles, improve prediction accuracy, and enable teams to rapidly move from concept to human data with speed, precision, and capital efficiency.

Antibodies & Bispecifics

AI/ML powered end-to-end discovery services and proprietary platforms

We put AI/ML at the center of antibody and bispecific discovery —streamlining campaigns from design to IND. Our in vivo platforms, generative modeling, and in silico developability tools work together to rapidly produce high-quality, de-risked candidates ready for downstream development.

Alloy Therapeutics Biologics Drug Discovery
TCR Mimics

Unlock new targets with TCRms

TCRm antibodies mimic the function of T-cell receptors by targeting intracellular peptides presented on cell surface MHC complexes (pMHC), opening up a wide range of intracellular targets in oncology and infectious disease. Keyway™ TCRm discovery is the first fully integrated platform and service, combining our world-class antibody discovery expertise with the pioneers of TCR therapeutics.

TCRm antibodies graphic
Genetic medicines

Empowering breakthroughs with Alloy’s antisense platform

Alloy Therapeutics integrates AI/ML with foundational antisense technologies to overcome the therapeutic index and delivery barriers that have historically limited ASO drug candidates. Collaborate with us to rapidly refine existing sequences or design de novo molecules in our Anticlastic™ format—a transiently cyclized structure engineered for improved potency, safety, and scalability.

ASO drug candidate graphic
Cell Therapies

Next-gen cell therapies designed for speed, safety, and scale

A versatile T cell platform delivers off-the-shelf cell therapies with enhanced safety, potency, and scalability. Engineered with γδTCRs, customizable CARs and armoring technologies, built on Alloy’s hypoimmune iPSC platform, it enables rapid innovation, reduces risks such as GvHD and host rejection, lowers manufacturing costs, and accelerates the clinical development of next-generation therapies.

T cell platform graphic

Connect with us at upcoming events

Alloy Therapeutics upcoming events graphic

Jan. 12-15, 2026

JPM

San Francisco, CA

Jan. 19-22 2026

Peptalk

San Diego, CA

Mar. 24-25 2026

NextGen BioMed

London, UK
antibody discovery graphic

Collaboration among scientists, competition against disease

We collaborate with our partners to leverage the full potential of our technology and services, acting as an innovation engine for the drug discovery industry.